Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
暂无分享,去创建一个
Alexander Gutin | Victor Abkevich | Michael Perry | A. Zharkikh | A. Gutin | J. Reid | V. Abkevich | D. Iliev | J. Lanchbury | T. Tran | K. Timms | E. Tikishvili | Kirsten M Timms | Jerry S Lanchbury | B. Morris | Andrey Zharkikh | Elisha Hughes | Chris Neff | Julia Reid | Brian Morris | Saritha Kalva | Jennifer Potter | Thanh V Tran | Jian Chen | Diana Iliev | Zaina Sangale | Eliso Tikishvili | C. Neff | Z. Sangale | Elisha Hughes | M. Perry | J. Potter | Saritha Kalva | Jian Chen | Zaina Sangale | Eliso Tikishvili
[1] L. Tsui,et al. A suggested nomenclature for designating mutations , 1993, Human mutation.
[2] G. Mills,et al. Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer , 2011, Clinical Cancer Research.
[3] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[4] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[5] G. Mills,et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.
[6] A. Vincent-Salomon,et al. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. , 2012, Cancer research.
[7] Christopher I Amos,et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[9] J. Lubiński,et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Thomas D. Wu,et al. Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes , 2009, Molecular Cancer Research.
[11] S. Narod,et al. Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] K. Offit,et al. Prevalence of BRCA1 and BRCA2 mutations in Jewish women with triple negative breast cancer , 2008 .
[13] Kirstin C. Jensen,et al. Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC) , 2012 .
[14] Stephanie A Cohen,et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.
[15] R. Wenstrup,et al. Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer , 2012, Cancer.
[16] Z. Szallasi,et al. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. , 2012, Cancer discovery.